Trial Profile
A Randomised, Double-Blind, Placebo-Controlled, 2-Period Cross-Over Study to Evaluate the Effect of Treatment With GSK2190915 on the Allergen-Induced Asthmatic Response in Subjects With Mild Asthma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Aug 2023
Price :
$35
*
At a glance
- Drugs Fiboflapon (Primary)
- Indications Asthma
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Sponsors GSK
- 28 Sep 2011 Pharmacodynamic results assessing the effect of treatment on leukotriene levels presented at the 21st Annual Congress of the European Respiratory Society.
- 28 Sep 2011 Results presented at the 21st Annual Congress of the European Respiratory Society.
- 01 Apr 2011 Planned end date changed from 1 Mar 2009 to 1 Sep 2009 as reported by ClinicalTrials.gov.